Sosei Looks To Add Value Through Pipeline Progress
Executive Summary
Japan-based Sosei is building up its portfolio of in-house assets on top of technology and molecule licensing deals as it looks to create value over the next few years following the acquisition of Heptares, say executives.
You may also be interested in...
Sosei CEO Says Recent $199m Equity Raising Will Help Pipeline Expansion
Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.